{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:36:40Z","timestamp":1789501000479,"version":"build-2803163510"},"reference-count":27,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2025,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>LIGHT (oLaparib In HRD\u2010Grouped Tumor types; NCT02983799) prospectively evaluated olaparib treatment in patients with platinum\u2010sensitive relapsed ovarian cancer (PSROC) assigned to cohorts by known BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: germline BRCAm (gBRCAm), somatic BRCAm (sBRCAm), HRD\u2010positive non\u2010BRCAm, and HRD\u2010negative. At the primary analysis, olaparib treatment demonstrated activity across all cohorts, with greatest efficacy in terms of objective response rate and progression\u2010free survival observed in the g\/sBRCAm cohorts. The authors report final overall survival (OS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this phase 2, open\u2010label, noncomparative study, patients with PSROC and one or more prior line of platinum\u2010based chemotherapy were assigned to cohorts by BRCAm and HRD status. OS was a secondary end point. Tumors were analyzed using Myriad BRACAnalysis CDx and MyChoice CDx assays; HRD\u2010positive tumors were defined using a genomic instability score of \u226542.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 272 enrolled patients, 271 received olaparib and 270 met the inclusion criteria for the efficacy analysis. At data cutoff, 18\u2010month OS rates in the gBRCAm, sBRCAm, HRD\u2010positive non\u2010BRCAm, and HRD\u2010negative cohorts were 86.4%, 88.0%, 78.6%, and 59.6%, respectively. No new safety signals were observed. In a post hoc analysis, patients on treatment for &gt;18 months were most frequently present in g\/sBRCAm cohorts (31.0%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Olaparib treatment continued to demonstrate benefit across all cohorts. Consistent with the primary analysis, the highest OS rates were observed in the BRCAm cohorts, regardless of g\/sBRCAm. In patients without a BRCAm, a higher OS rate was observed in the HRD\u2010positive non\u2010BRCAm than the HRD\u2010negative cohorts. These results highlight the importance of biomarker testing in this treatment setting.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.35707","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T07:44:34Z","timestamp":1737013474000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Olaparib as treatment for platinum\u2010sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis"],"prefix":"10.1002","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5790-851X","authenticated-orcid":false,"given":"Ying L.","family":"Liu","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center  New York New York USA"},{"name":"Weill Cornell Medical College  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara A.","family":"Mathews","sequence":"additional","affiliation":[{"name":"Program in Women\u2019s Oncology Department of Obstetrics and Gynecology Women and Infants Hospital Legoretta Cancer Center Brown University  Providence Rhode Island USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0840-2368","authenticated-orcid":false,"given":"Fiona","family":"Simpkins","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Jordan Center for Gynecologic Oncology at the Abramson Cancer Center University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen A.","family":"Cadoo","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center  New York New York USA"},{"name":"St. James\u2019s Hospital Dublin Trinity St. James\u2019s Cancer Institute Trinity College Dublin  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Provencher","sequence":"additional","affiliation":[{"name":"Division of Gynecologic\u2010Oncology Centre de recherche du Centre hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al  Montr\u00e9al Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen C.","family":"McCormick","sequence":"additional","affiliation":[{"name":"Legacy Medical Group Gynecologic Oncology  Portland Oregon USA"},{"name":"The Johns Hopkins Hospital  Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam C.","family":"ElNaggar","sequence":"additional","affiliation":[{"name":"West Cancer Center and Research Institute  Memphis Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6345-4910","authenticated-orcid":false,"given":"Alon D.","family":"Altman","sequence":"additional","affiliation":[{"name":"CancerCare Manitoba Research Institute of Oncology and Hematology University of Manitoba  Winnipeg Manitoba Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology McGill University Health Centre and The Gerald Bronfman Department of Oncology McGill University  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Destin","family":"Black","sequence":"additional","affiliation":[{"name":"Willis\u2010Knighton Cancer Center  Shreveport Louisiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nashwa","family":"Kabil","sequence":"additional","affiliation":[{"name":"AstraZeneca  Gaithersburg Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosie N.","family":"Taylor","sequence":"additional","affiliation":[{"name":"AstraZeneca  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Barnicle","sequence":"additional","affiliation":[{"name":"AstraZeneca  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiefen Y.","family":"Munley","sequence":"additional","affiliation":[{"name":"AstraZeneca  Wilmington Delaware USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center  New York New York USA"},{"name":"Weill Cornell Medical College  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.06.017"},{"key":"e_1_2_11_3_1","unstructured":"AstraZeneca.Global policy: bioethics. Accessed July 19 2023.https:\/\/www.astrazeneca.com\/content\/dam\/az\/PDF\/Sustainability\/Code_of_Ethics_English.pdf"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02745"},{"issue":"7","key":"e_1_2_11_5_1","doi-asserted-by":"crossref","first-page":"S790; abstract","DOI":"10.1016\/j.annonc.2022.07.659","article-title":"Maintenance olaparib monotherapy in patients (pts) with platinum\u2010sensitive relapsed ovarian cancer (PSR OC) without a germline BRCA1\/BRCA2 mutation (non\u2010gBRCAm): final overall survival (OS) results from the OPINION trial","volume":"33","author":"Poveda A","year":"2022","journal-title":"Ann Oncol"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(17)30469\u20102"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(22)00122\u2010X"},{"key":"e_1_2_11_8_1","unstructured":"Clovis Oncology.Dear Health Care Provider Letter (Rucaparib). Accessed October 16 2023.https:\/\/www.ema.europa.eu\/en\/documents\/dhpc\/direct\u2010healthcare\u2010professional\u2010communication\u2010dhpc\u2010rubraca\u2010rucaparib\u2010restriction\u2010indication_en.pdf"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090\u20108258(22)01244\u20106"},{"key":"e_1_2_11_10_1","article-title":"Overall survival by number of prior lines of chemotherapy in patients with BRCA\u2010mutated platinum\u2010sensitive relapsed ovarian cancer receiving olaparib treatment or non\u2010platinum chemotherapy in SOLO3","author":"Leath CA,","year":"2022","journal-title":"IGCS 2022 Annual Global Meeting"},{"key":"e_1_2_11_11_1","unstructured":"AstraZeneca.Dear Health Care Provider Letter (Olaparib). Accessed July 19 2023.https:\/\/www.lynparzahcp.com\/content\/dam\/physician\u2010services\/us\/590\u2010lynparza\u2010hcp\u2010branded\/hcp\u2010global\/pdf\/solo3\u2010dhcp\u2010final\u2010signed.pdf"},{"key":"e_1_2_11_12_1","unstructured":"Lynparza.Prescribing information.AstraZeneca. Accessed January 18 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/208558s028lbl.pdf"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(19)30029\u20104"},{"key":"e_1_2_11_14_1","unstructured":"GlaxoSmithKline.Dear Health Care Provider Letter (Niraparib). Accessed July 19 2023.https:\/\/www.zejulahcp.com\/content\/dam\/cf\u2010pharma\/hcp\u2010zejulahcp\u2010v2\/en_US\/pdf\/ZEJULA%20(niraparib)%20Dear%20HCP%20Letter%20September%202022.pdf"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01549"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.05.005"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090\u20108258(22)01528\u20101"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010021\u201022582\u20106"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.08.021"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.11.019"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.03.019"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.12.025"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1182"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2021.100699"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.Ccr\u201022\u20103282"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2022.100939"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.3110"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.11.003"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.35707","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:25:38Z","timestamp":1760264738000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.35707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1,15]]}},"alternative-id":["10.1002\/cncr.35707"],"URL":"https:\/\/doi.org\/10.1002\/cncr.35707","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"2024-08-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e35707"}}